# A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization

> **NCT01157455** · PHASE4 · UNKNOWN · sponsor: **CCRF Consulting Co., Ltd.** · enrollment: 1900 (estimated)

## Conditions studied

- Coronary Artery Diseases

## Interventions

- **PROCEDURE:** Everolimus Drug Eluting Stent
- **DRUG:** Aspirin
- **DRUG:** Clopidogrel
- **DRUG:** Heparin or Bivalirudin

## Key facts

- **NCT ID:** NCT01157455
- **Lead sponsor:** CCRF Consulting Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2012-03
- **Final completion:** 2013-06
- **Target enrollment:** 1900 (ESTIMATED)
- **Last updated:** 2010-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157455, "A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01157455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*